ArticleAmerican journal of hematology2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Anthony R Mato et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
33 papers cite it
this paperpooled ittrialcites it